Compositions Comprising Rank/Rankl Antagonists and Related Compounds for Treating Pain

Abstract

Disclosed herein are methods of treating pain using comprising RANK/RANKL antagonists.

What is claimed is: 
     
         1 . A method of treating pain comprising orally administering zoledronic acid to relieve inflammatory pain in a human being in need thereof, wherein the inflammatory pain is located in the low back or in a joint, wherein the human being receives about 80 mg to about 600 mg of zoledronic acid within a period of two months, wherein zoledronic acid is administered as 3 to 8 divided doses that are administered no more often than once a week, wherein the human being experiences pain relief that lasts for a duration of at least 48 hours. 
     
     
         2 . The method of  claim 1 , further comprising administering a second therapeutic agent indicated for the treatment of pain or another neurological disorder. 
     
     
         3 . The method of  claim 1 , wherein the human being does not have cancer. 
     
     
         4 . The method of  claim 1 , wherein the inflammatory pain is arthritis pain. 
     
     
         5 . The method of  claim 1 , wherein the inflammatory pain is associated with osteoarthritis of the knee. 
     
     
         6 . The method of  claim 1 , wherein the zoledronic acid is administered weekly. 
     
     
         7 . The method of  claim 1 , wherein the dose is administered to the human being after at least one hour of fasting. 
     
     
         8 . The method of  claim 1 , wherein the human being receives about 40 mg to about 300 mg of zoledronic acid per month. 
     
     
         9 . The method of  claim 1 , wherein the zoledronic acid is administered weekly for 4 to 8 consecutive weeks. 
     
     
         10 . The method of  claim 1 , wherein the zoledronic acid is administered weekly for 6 consecutive weeks. 
     
     
         11 . A method of treating pain comprising orally administering zoledronic acid to relieve inflammatory pain in a human being in need thereof, wherein the inflammatory pain is located in the low back or in a joint, wherein the human being receives about 100 mg to about 600 mg of zoledronic acid within a period of three months, wherein the zoledronic acid is administered no more often than weekly, and wherein the human being experiences pain relief that lasts for a duration of at least 48 hours. 
     
     
         12 . The method of  claim 11 , wherein the zoledronic acid is administered in divided doses. 
     
     
         13 . The method of  claim 12 , wherein the zoledronic acid is divided into two or three doses. 
     
     
         14 . The method of  claim 13 , wherein the zoledronic acid is administered in two doses. 
     
     
         15 . The method of  claim 13 , wherein the zoledronic acid is administered in three doses. 
     
     
         16 . The method of  claim 11 , wherein about 100 mg to about 200 mg of zoledronic acid is administered per dose. 
     
     
         17 . The method of  claim 11 , wherein at least about 150 mg of zoledronic acid is administered at least twice a month. 
     
     
         18 . The method of  claim 11 , wherein three divided doses of totaling at least 450 mg of zoledronic acid is administered within a period of two months. 
     
     
         19 . The method of  claim 11 , wherein three divided doses of about 150 mg to about 180 mg each of zoledronic acid are administered within a period of two months. 
     
     
         20 . The method of  claim 11 , wherein about 200 mg to about 300 mg of zoledronic acid is administered once. 
     
     
         21 . The method of  claim 11 , wherein the inflammatory pain is associated with complex regional pain syndrome (CRPS). 
     
     
         22 . A method of treating pain comprising orally administering zoledronic acid to relieve inflammatory pain in a human being in need thereof, wherein the inflammatory pain is located in the low back or in a joint, wherein the human being receives about 10 mg to about 300 mg of zoledronic acid within a period of two months, wherein zoledronic acid is administered no more often than once a week, and wherein the human being experiences pain relief that lasts for a duration of at least 48 hours. 
     
     
         23 . The method of  claim 22 , wherein the inflammatory pain is arthritis pain. 
     
     
         24 . The method of  claim 22 , wherein the inflammatory pain is associated with osteoarthritis of the knee. 
     
     
         25 . The method of  claim 22 , wherein the inflammatory pain is associated with complex regional pain syndrome (CRPS). 
     
     
         26 . The method of  claim 22 , wherein about 10 to about 30 mg of zoledronic acid is administered every week. 
     
     
         27 . The method of  claim 22 , wherein zoledronic acid is administered weekly for at least four weeks. 
     
     
         28 . The method of  claim 22 , wherein zoledronic acid is administered for a period between about four weeks to about eight weeks. 
     
     
         29 . The method of  claim 22 , wherein about 60 to about 200 mg of zoledronic acid is administered over a period of four to eight weeks. 
     
     
         30 . The method of  claim 22 , wherein about 10 mg to about 30 mg of zoledronic acid is administered once a week for at least four weeks.